34503-87-2
34503-87-2
Chemical Structure
Polymyxin B2
- CAS No.: 34503-87-2
- Formula:C55H96N16O13
- Molecular Weight:1189.45
IUPAC Name: N-((S)-4-amino-1-(((2S,3R)-1-(((S)-4-amino-1-oxo-1-(((3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-((R)-1-hydroxyethyl)-12-isobutyl-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclotricosan-21-yl)amino)butan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)amino)-1-oxobutan-2-yl)-6-methylheptanamide
InChIKey: SGPYLFWAQBAXCZ-RUDZPDEXSA-N
SMILES: O=C(N[C@H](C(N[C@@](C(N[C@H](C(N[C@@]1([H])[C@H](O)C)=O)CCN)=O)([H])CCN)=O)CC(C)C)[C@H](NC([C@@H](NC([C@@](CCNC1=O)([H])NC([C@H](CCN)NC([C@H]([C@H](O)C)NC([C@H](CCN)NC(CCCCC(C)C)=O)=O)=O)=O)=O)CCN)=O)CC2=CC=CC=C2
Biological Activity: Polymyxin B2 is a polypeptide antibiotic with particularly potent antibacterial activity against Gram-negative bacteria. Polymyxin B2 kills bacteria by binding to lipopolysaccharide molecules on the bacterial cell membrane, disrupting membrane integrity and causing leakage of intracellular contents. Polymyxin B2 is used in studies related to Pseudomonas aeruginosa infection and acute enteritis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Polymyxin B2 | 99.59% | Polymyxin B2 is a polypeptide antibiotic with particularly potent antibacterial activity against Gram-negative bacteria. Polymyxin B2 kills bacteria by binding to lipopolysaccharide molecules on the bacterial cell membrane, disrupting membrane integrity and causing leakage of intracellular contents. Polymyxin B2 is used in studies related to Pseudomonas aeruginosa infection and acute enteritis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Polymyxin B2 (Standard) | ≥98% | Polymyxin B2 (Standard) is the analytical standard of Polymyxin B2 (HY-A0248B). This product is intended for research and analytical applications. Polymyxin B2 is a polypeptide antibiotic with particularly potent antibacterial activity against Gram-negative bacteria. Polymyxin B2 kills bacteria by binding to lipopolysaccharide molecules on the bacterial cell membrane, disrupting membrane integrity and causing leakage of intracellular contents. Polymyxin B2 is used in studies related to Pseudomonas aeruginosa infection and acute enteritis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Polymyxin B nonapeptide | 99.97% | Polymyxin B nonapeptide is a cyclic peptide obtained from Polymyxin B by proteolytic removal of its terminal amino acyl residue. Polymyxin B nonapeptide is less toxic, lacks bactericidal activity, and retains its ability to render gram-negative bacteria susceptible to several antibiotics by permeabilizing their outer membranes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Colistin B | Colistin B (Polymyxin E2) is a major component of Colistin (HY-113678) and also an antibacterial agent active against multidrug-resistant Gram-negative bacteria. Colistin B exerts apoptotic effects on human renal proximal tubular cells. Colistin B induces mild to moderate renal histological damage in mouse models. Colistin B can be used in the research of multidrug-resistant Gram-negative bacterial infections. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Polymyxin B1 | 99.25% | Polymyxin B1 is a potent antimicrobial lipopeptide first derived from Bacilus polymyxa. Polymyxin B1 is the major component in Polymyxin B (HY-A0248). Polymyxin B1 can induce lysis of bacterial cells through interaction with their membranes. Polymyxin B1 has the potential for multidrug-resistant Gram-negative bacterial infections treatment. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Polymyxin A2 | Polymyxin A2 is a heteropeptide antibiotic found in different strains of Bacillus polymyxa, and its effect against Gram-negative bacteria is greater than that against Gram-positive bacteria. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Polymyxin P1 | Polymyxin P1 is a lipopeptide antibiotic belonging to the Polymyxin family, and it is a secondary metabolite produced by the rhizosphere bacterium Paenibacillus polymyxa M-1. Polymyxin P1 binds to bacterial outer membrane lipopolysaccharides, permeabilizes cell membranes, and induces dense protrusions on the cell surface of phytopathogenic Erwinia strains. Polymyxin P1 inhibits the growth of phytopathogenic Erwinia amylovora and E. carotovora. Polymyxin P1 can be used for the research of fire blight and soft rot. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Polymyxin P2 | Polymyxin P2 is found in Bacillus polymyxa T-39 and can inhibit Gram-positive bacteria. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Polymyxin S1 | Polymyxin S1 is found in Bacillus Polymyxa RS-6 and is resistant to Gram-positive bacteria. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Polymyxin T1 | Polymyxin T1 is an antibiotic found in Bacillus polymyxa E-12. Polymyxin T1 has an effect against Gram-negative bacteria and a weak effect against Gram-positive bacteria. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
NAB815 | NAB815 is a specific inhibitor of the Stx2a (Kd = 0.01 μM)/TLR4 interaction. NAB815 inhibits the neutrophil/Stx2a interaction (IC50 = 0.057 μg/mL). NAB815 inhibits the formation of Stx2-containing extracellular vesicles (EVs) produced by leukocytes and platelets and reduces their toxic effects in cellular (Vero cells) and animal models (CD-1 mice). NAB815 reduces bacterial loads in the kidneys, urine, and bladders of Escherichia coli-infected mice. NAB815 is useful in the study of hemolytic uremic syndrome (HUS). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SPR741 | 99.53% | SPR741 (NAB741) is a cationic peptide derived from polymyxin B and is a potentiator molecule. SPR741 increases the permeability of the outer membrane of Gram-negative bacteria and is used to treat severe Gram-negative bacteria infections. SPR741 inhibits multidrug-resistant Gram-negative bacteria. The spectrum of activity of the antibiotic can be widened when used in combination with SPR741. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Han W, et al. New antimicrobial peptide-antibiotic combination strategy for Pseudomonas aeruginosa inactivation. Biointerphases. 2022;17(4):041002. Published 2022 Aug 3. [Content Brief]
-
[2]. Zheng L, et al. Lactiplantibacillus plantarum and Saccharomyces cerevisiae-Fermented Coconut Water Alleviates Dextran Sodium Sulfate-Induced Enteritis in Wenchang Chicken: A Gut Microbiota and Metabolomic Approach. Animals (Basel). 2024 Feb 8;14(4):575.
[Content Brief]
